IIR’s 14th Annual Immunogenicity for Biotherapeutics event is three weeks away! We invite you to join the leaders in biologics de-risking, immunoassay validation and predicting immunogenicity in novel, highly complex molecules. Below is just a small portion of who’s already signed up to be in Baltimore March 18-20th:Companies in attendance include:
*Adnexus * Advion * Alexion Pharmaceuticals * Algorithme Pharma * Allergan * Amgen * Astellas Pharma Global Development * Aushon Biosystems * Avanza Laboratories * Bayer Healthcare * Biogen Idec * Boehringer Ingelheim Pharmaceuticals * Bristol-Myers Squibb * CDER * Charles River Laboratories * CIRION Clinical Trial Services * Clinigene International * Covance * Cytimmune Science * Eleven Biotherapeutics * Eli Lilly & Co. * Emory Children's Center * EpiVax * Food and Drug Administration * Frederick National Lab for Cancer Research * Functional Genetics * Genentech * Genzyme Corp * GlaxoSmithKline * Grifols * Hospira * Ipsen Group * Isis Pharmaceuticals * Janssen * KCAS Bioanalytical Services * Kirin Pharma * MedImmune * PerkinElmer * PharmaNet Development Group * PPD * QPS * Sandoz * Sanofi * Seattle Genetics * SQI Diagnostics * Teva Biopharmaceuticals * WIL Research * and more!
If you’d like to join these companies, the Immunogenicity for Biotherapeutics Conference is taking place next week, March 18-20, 2013, in Baltimore, MD. As a reader of this blog, you receive an exclusive discount of 15% off the standard rate when you register using code XP1838Link.
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment